Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03378934 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Anti-platelet Effect of Berberine in Patients After Percutaneous Coronary Intervention

Study acronym: APLABE-PCI
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated November 19, 2025 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Jun 2025 to Jun 2026 Completion date: Aug 2025 to Aug 2026v9 Show 1 more changeShow less
    • Completion date: Aug 2025 to Aug 2026
  2. Primary completion date: Jun 2023 to Jun 2025 Completion date: Jun 2023 to Aug 2025v8 Show 1 more changeShow less
    • Completion date: Jun 2023 to Aug 2025
  3. Primary completion date: Nov 2021 to Jun 2023 Completion date: Dec 2021 to Jun 2023v7 Show 1 more changeShow less
    • Completion date: Dec 2021 to Jun 2023
  4. Primary completion date: Nov 2020 to Nov 2021 Completion date: Dec 2020 to Dec 2021v6 Show 1 more changeShow less
    • Completion date: Dec 2020 to Dec 2021
  5. Primary completion date: Mar 2020 to Nov 2020 Completion date: Apr 2020 to Dec 2020 · Eligibility criteria shortened, about 16 words · Study description shortened, about 26 words · 1 morev5 Show 4 more changesShow less
    • Completion date: Apr 2020 to Dec 2020
    • Eligibility criteria shortened, about 16 words
    • Study description shortened, about 26 words
    • Study title shortened, about 1 word

    See this version in full on ClinicalTrials.gov ↗

Show 3 earlier versionsHide 3 earlier versions
  1. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Start date changed from estimate of Sep 2018 to Sep 26, 2018 · Eligibility criteria expanded, about 28 words · 3 morev4 Show 6 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of Sep 2018 to Sep 26, 2018
    • Eligibility criteria expanded, about 28 words
    • Secondary endpoints: 14 to 8
    • Study description expanded, about 96 words
    • Study title shortened, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  2. Start date: May 2018 to Sep 2018v3
  3. Start date: Jan 2018 to May 2018v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The APLABE-PCI is a single-center, randomized, open-label, controlled, dose-escalating, parallel-group study, which is designed to assess the anti-platelet effect of berberine in approximately 64 patients receiving aspirin and clopidogrel who are at \> 8 but ≤ 40 weeks after percutaneous coronary intervention.
Trial Details
NCT Number NCT03378934
Lead Sponsor Peking Union Medical College Hospital
Conditions Coronary Artery Disease, Percutaneous Coronary Intervention
Enrollment 64 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov